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Abstract 
BACKGROUND: Pemphigus Vulgaris (PV) is a chronic disease, is characterized by the presence of flacid bullous 
in skin and mucosa. There are 2 main autoantibodies against desmoglein3 (Dsg3) and desmoglein1 (Dsg1). 
AIM: The aims of this study were to evaluate the before and after treatment outcome with corticosteroid, using 
Desmoglein ELISA test. 
METHOD: Forty patients with Pemphigus include 36 PV and 4 PF (28 women, 12 women) were enrolled. The 
titers of Dsg in pemphigus patients by using ELISA test were done before and 1-month treatment  
RESULTS: Both anti-Dsg1 and anti-Dsg3 levels were significantly reduced after treatment (P < 0.05). The 
severity of skin lesions was correlated with anti-Dsg1 antibody level and the severity of oral lesions was 
significantly correlated with anti-Dsg 3 antibody levels (p < 0.05) 
CONCLUSION: It is recommended that we can predict and improve the outcome of treatment by using 
Desmoglein ELISA test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Pemphigus is a group acquired autoimmune 
bullous skin disease, it is characterized by flaccid 
blisters on the skin and mucous membranes, caused 
by acantholysis phenomenon (Amagai.M, Ishii.K et al. 
1997) [1]. There are 2 main subtypes: Pemphigus 
vulgaris (P.V) and Pemphigus foliaceus (P.F). The 
pathogenic of disease is characterized by the 
presence of autoantibodies against desmosomal 
glycoproteins, including desmoglein 3 (Dsg3) in P.V 
and desmoglein 1 (Dsg1) in P.F. ELISA is a 
quantitative method for measuring antibody levels and 
a useful test for the diagnosis of pemphigus.  
We tried to find the value of Dsg 1,3 by ELISA 
to predict the severity and monitoring this disease 
before and after treatment. 
 
 
Methods 
 
Based on clinical presentation and 
histopathology, from July 2013 to September 2014, 
forty pemphigus patients (36 PV, 4 PF) were enrolled 
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in this study, including 28 women and 12 men. Mean 
age of male was 40.1 ± 9.0 years and of females was 
51.3 ± 14.0 years. Dsg ELISA testing was performed 
on the sera of 40 patients before and after 1-month 
treatment. Anti-desmoglein autoantibodies were 
detected by ELISA method (kits from Medical and 
Biological Laboratories Co Ltd. Nagoya, Japan) with 
100-fold serum dilution. The index value of positive 
reactions was considered greater than 20 U/L. 
SPSS 20.0 software was used to analyse the 
data. Paired t-test was used to determine the 
difference in the anti-Dsg index values before and 
after treatment. P < 0.05 was considered significant. 
 
 
Results  
 
Forty patients with pemphigus (12 men, 28 
women) were enrolled. The mean ± SD age was 48.0 
± 13.6 years, with a range of 15 to 80 years. The most 
frequent phenotype was muco-cutaneous in 25/40 
(62,5%) cases, mucosal dominant and cutaneous 
dominant phenotypes were seen in 1/40 (2,5%) and 
14/40 (35%) cases, respectively.  
Table 1: Distribution of anti-Dsg ELISA 
Level Cutaneous 
lesions 
Dsg 1 
positive 
Dsg3 
positive 
Mucosal 
lesions 
Dsg 1 
positive 
Dsg 3 
positive 
No lesion 1 0 1 14 13 7 
Mild 5 3 4 13 11 11 
Moderate 23 20 16 13 10 13 
Severe 11 11 10 0 0 0 
 
The changes of the mean anti-Dsg1 and anti-
Dsg3 index values (± SD) before and after treatment 
are shown in Table 2. The decrease in the mean anti-
Dsg1 and antiDsg3 index values was statistically 
significant with a p-value below 0.05. 
Table 2: Anti-Dsg ELISA before and after 1- month treatment 
Disease 
Dsg 1 (U/L) Dsg 3 (U/L) 
Before After Before After 
PV 81. 5 ± 52.5 67.8 ± 53.4 91.2 ± 54.1 65.6 ± 53.3 
PF 138.3 ± 38.3 94.7 ± 40.7 56.6 ± 23.3 28.2 ± 19.1 
Total 87.2 ± 53.7 61.5 ± 53.0 87.7 ± 55.1 60.9 ± 53.1 
p < 0.05 < 0.05 
 
 
 
Discussion 
 
There are many documents report about the 
relationship between desmoglein titer and the severity 
of pemphigus disease. Amagai et al., (1999) used 
ELISA test in serum pemphigus patients showed 
97.9% of P.F patients were positive with anti-Dsg 1 
and 97.5% of P.V patients were positive with anti-Dsg 
3 (Lenz, Amagai et al. 1999) [2]. Harman et al (2000) 
showed that the sensitivity of the ELISA in diagnosing 
Pemphigus is above 98% and in those patients 
untreated, the sensitivity was 100% (Harman, Gratian 
et al. 2000) [3]. Daneshpazhooh et al (2007) found 
that the rate of positive is 76.1% with anti- Dsg1; with 
anti- Dsg 3 is 94.5% (Daneshpazhooh, Chams-
Davatchi et al. 2007) [4]. In many other studies also 
showed anti-Dsg has generally higher, ranging from 
80 to 100% depending on each author (Anand, 
Khandpur et al. 2012; Avgerinou, Papafragkaki et al. 
2013; Bracke, Speeckaert et al. 2013) [5], [6], [7]. 
Many studies have shown that this technique is highly 
sensitive and high specificity and it can evaluate the 
correlation between antibody concentration and the 
degree of activity (Marinovic, Fabris et al. 2010; 
Schmidt, Dähnrich et al. 2010; Anand, Khandpur et al. 
2012; Bracke, Speeckaert et al. 2013) [5], [7], [8], [9]. 
Recently, it using as a marker to diagnosing and 
monitoring the severity of a disease. It is believed that 
oral dominant pemphigus is characterized by the 
presence of anti-Dsg3, and anti-Dsg 1 is in cutaneous 
dominant (Aoyama, Tsujimura et al. 2000; Harman, 
Gratian et al. 2000; Abasq, Mouquet et al. 2009; 
Bracke, Speeckaert et al. 2013) [3], [7], [10], [11]. On 
the other hand, studies regarding the correlation 
between the severity of this disease and anti-Dsg 
levels as well as its value in monitoring the disease 
are. Our results also showed that anti-Dsg ELISA is a 
simple method and highly valuable in the diagnosis.  
There was a statistically significant correlation 
was seen between Dsg1 index values and severity of 
skin involvement and direct statistically significant 
correlation was seen between Dsg3 index values and 
the severity of oral involvement. Mortazavi et al (2009) 
showed that: the degree of skin damages a significant 
increase with anti-Dsg1 concentrations, and there was 
a relationship between the level of mucosal lesions 
with anti-Dsg3 (Mortazavi, Shahdi et al. 2009) [12].  
Both anti-Dsg1 and anti-Dsg3 levels were 
significantly reduced after 1-month treatment (p < 
0.05). In some studies also concluded that there was 
significant decrease level of Dsg after treatment. 
(K.E.Harman, P.T.Seed et al. 2001; Kumar, Arora et 
al. 2006; Bracke, Speeckaert et al. 2013) [7], [13], 
[14], [15].  
In conclusion, Dsg ELISA is not only a 
sensitive tool for diagnosis of PV, but also has a 
predictive means of its severity as well as for 
monitoring the activity and relapse of disease. 
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